The firm, an India-based producer of active pharmaceutical ingredients (APIs) and drug intermediates, has extended its development-scale synthetic peptide production offering to a full commercial scale manufacturing service.
Company VP of R&D, MK Anwer, said: “Our expanded service provides rapid access to commercial quantities of affordable, high quality peptides from a company with a 27-year track record of consistently achieving the highest regulatory standards in global pharmaceutical production."
Dr Anwer added: "Our researchers have developed expertise in producing peptides of varying lengths and complexity. We are especially proud of our success in applying advanced methods for handling the aggregation and purification issues inherent in manufacturing long and complex peptides.
Neuland CEO Sucheth Davuluri focused on the expansion’s commercial potential, suggesting that: “At a time when efficiency is critical to business success, we expect that our commitment to cost effectiveness, regulatory rigor and customer service will be a welcome option for peptide researchers and manufacturers.”
Indian-based Neuland first proposed building additional manufacturing capacity in 2008, predicting increasing demand in an expanding global pharmaceutical market.
This process accelerated the following year when Neuland started building a facility to produce highly potent active pharmaceutical ingredients (HPAPI) and peptides in an effort to expand it business in the US and European markets.
And, judging by its most recent set of financials, the strategy is paying off. Neuland’s contract research and manufacturing and peptides units posted strong full year sales with revenue of $88.8m (€63.4m) in fiscal 2011, up 41 per cent year-on-year.